Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy

Abstract Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half‐lives, the typical duration used to guide pre‐operative medication recommendations.

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	David Bobrowski, Reha Kumar, Peter E. Wu, Lauren Lapointe‐Shaw
Format:	article
Langue:	EN
Publié:	Wiley 2021
Sujets:	diabetes euglycemic diabetic ketoacidosis sodium‐glucose cotransporter 2 inhibitors Medicine R Medicine (General) R5-920
Accès en ligne:	https://doaj.org/article/34c939d53002417eb7eb7864524bb8df
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:34c939d53002417eb7eb7864524bb8df
record_format	dspace
spelling	oai:doaj.org-article:34c939d53002417eb7eb7864524bb8df2021-12-01T06:36:08ZProlonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy2050-090410.1002/ccr3.5057https://doaj.org/article/34c939d53002417eb7eb7864524bb8df2021-11-01T00:00:00Zhttps://doi.org/10.1002/ccr3.5057https://doaj.org/toc/2050-0904Abstract Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half‐lives, the typical duration used to guide pre‐operative medication recommendations.David BobrowskiReha KumarPeter E. WuLauren Lapointe‐ShawWileyarticlediabeteseuglycemic diabetic ketoacidosissodium‐glucose cotransporter 2 inhibitorsMedicineRMedicine (General)R5-920ENClinical Case Reports, Vol 9, Iss 11, Pp n/a-n/a (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetes euglycemic diabetic ketoacidosis sodium‐glucose cotransporter 2 inhibitors Medicine R Medicine (General) R5-920
spellingShingle	diabetes euglycemic diabetic ketoacidosis sodium‐glucose cotransporter 2 inhibitors Medicine R Medicine (General) R5-920 David Bobrowski Reha Kumar Peter E. Wu Lauren Lapointe‐Shaw Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
description	Abstract Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half‐lives, the typical duration used to guide pre‐operative medication recommendations.
format	article
author	David Bobrowski Reha Kumar Peter E. Wu Lauren Lapointe‐Shaw
author_facet	David Bobrowski Reha Kumar Peter E. Wu Lauren Lapointe‐Shaw
author_sort	David Bobrowski
title	Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
title_short	Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
title_full	Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
title_fullStr	Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
title_full_unstemmed	Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
title_sort	prolonged ketosis and glycosuria secondary to sglt2 inhibitor therapy
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/34c939d53002417eb7eb7864524bb8df
work_keys_str_mv	AT davidbobrowski prolongedketosisandglycosuriasecondarytosglt2inhibitortherapy AT rehakumar prolongedketosisandglycosuriasecondarytosglt2inhibitortherapy AT peterewu prolongedketosisandglycosuriasecondarytosglt2inhibitortherapy AT laurenlapointeshaw prolongedketosisandglycosuriasecondarytosglt2inhibitortherapy
_version_	1718405467945828352

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy

Documents similaires